MacroGenics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Good afternoon. Thank you for joining us today for another session at our annual Global Healthcare Conference. I'm Brian Cheng. I'm the Senior Biotech Analyst here at Cantor. It's my pleasure to introduce to you next the management team from MacroGenics. Joining us is their President and CEO, Scott Koenig.
Scott, welcome, and thanks for joining us today.
Thank you very much, Brian. And thank you for the opportunity to present at the Cantor Conference. I will be making forward-looking statements during my presentation, so please refer to our SEC filings to understand the risks in investing in MacroGenics.
2021 was a year of significant advancement for MacroGenics. We launched MARGENZA, our first in-house developed proprietary product, with our partner EVERSANA in March. We significantly advanced our B7-H3 portfolio and continue to demonstrate the value of our technology platforms, which include our bispecific DART technology, our Fc Optimization
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |